26 November 2024 : Clinical Research
Sarcopenia's Role in Neoadjuvant Chemotherapy Outcomes for Locally Advanced Breast Cancer: A Retrospective Analysis
Mustafa Karaca1ACDEF, Mustafa Serkan Alemdar2BDF, Özge Deniz Karaca3ABEF, Yıldız Kılar4BD, Gökhan Köker3BEF, Hasan Sözel5CDE, Mustafa Yıldız2DEF, Gülhan Özçelik Köker1DEF, Mustafa Özgür Arici
2BDEF*
DOI: 10.12659/MSM.945240
Med Sci Monit 2024; 30:e945240
Table 7 Comparison of adverse effects in patients with comorbidities based on pre- and post-treatment sarcopenia status.
| Pre-NAC normal | Pre-NAC sarcopenia | P | ||||
|---|---|---|---|---|---|---|
| n | % | n | % | |||
| Absent | 37 | 64.9 | 5 | 29.4 | ||
| Present | 20 | 35.1 | 12 | 70.6 | ||
| Absent | 30 | 52.6 | 3 | 17.6 | ||
| Present | 27 | 47.4 | 14 | 82.4 | ||
| Absent | 33 | 66.0 | 9 | 37.5 | ||
| Present | 17 | 34.0 | 15 | 62.5 | ||
| Absent | 23 | 46.0 | 10 | 41.7 | 0.726 | |
| Present | 27 | 54.0 | 14 | 58.3 | ||
| NAC – neoadjuvant chemotherapy. values indicate statistical significance. * Fisher’s exact test. | ||||||